WO2003101374A3 - Utilisation de nouveaux esters d'etonogestrel - Google Patents

Utilisation de nouveaux esters d'etonogestrel Download PDF

Info

Publication number
WO2003101374A3
WO2003101374A3 PCT/EP2003/050188 EP0350188W WO03101374A3 WO 2003101374 A3 WO2003101374 A3 WO 2003101374A3 EP 0350188 W EP0350188 W EP 0350188W WO 03101374 A3 WO03101374 A3 WO 03101374A3
Authority
WO
WIPO (PCT)
Prior art keywords
new
etonogestrel esters
esters
new etonogestrel
contraceptively
Prior art date
Application number
PCT/EP2003/050188
Other languages
English (en)
Other versions
WO2003101374A2 (fr
Inventor
Nijs Henrik De
Der Voort Hendrikus Adrian Van
Dirk Leysen
Arij Jan Grootenhuis
Der Louw Jaap Van
Original Assignee
Akzo Nobel Nv
Nijs Henrik De
Der Voort Hendrikus Adrian Van
Dirk Leysen
Arij Jan Grootenhuis
Der Louw Jaap Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR10-2004-7019327A priority Critical patent/KR20050005507A/ko
Priority to DE60320786T priority patent/DE60320786D1/de
Application filed by Akzo Nobel Nv, Nijs Henrik De, Der Voort Hendrikus Adrian Van, Dirk Leysen, Arij Jan Grootenhuis, Der Louw Jaap Van filed Critical Akzo Nobel Nv
Priority to EP03755980A priority patent/EP1513588B1/fr
Priority to BR0311248-9A priority patent/BR0311248A/pt
Priority to US10/517,362 priority patent/US20050222114A1/en
Priority to AU2003246740A priority patent/AU2003246740B2/en
Priority to MXPA04011798A priority patent/MXPA04011798A/es
Priority to NZ536618A priority patent/NZ536618A/en
Priority to UA20041109285A priority patent/UA80703C2/uk
Priority to ES03755980T priority patent/ES2305498T3/es
Priority to JP2004508732A priority patent/JP2005532336A/ja
Priority to YU101004A priority patent/RS101004A/sr
Priority to CA002487293A priority patent/CA2487293A1/fr
Publication of WO2003101374A2 publication Critical patent/WO2003101374A2/fr
Publication of WO2003101374A3 publication Critical patent/WO2003101374A3/fr
Priority to IL16512504A priority patent/IL165125A0/xx
Priority to NO20044903A priority patent/NO20044903L/no
Priority to IS7537A priority patent/IS7537A/is
Priority to HR20041127A priority patent/HRP20041127A2/hr
Priority to HK05105351A priority patent/HK1072568A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

La présente invention concerne une trousse de contraception et/ou de traitement hormonal substitutif (THS) comprenant une quantité efficace d'un point de vue contraceptif et/ou thérapeutique d'un ester d'étonogestrel à action prolongée dont la chaîne grasse présente une longueur comprise entre C7 et C15.
PCT/EP2003/050188 2002-05-30 2003-05-22 Utilisation de nouveaux esters d'etonogestrel WO2003101374A2 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
JP2004508732A JP2005532336A (ja) 2002-05-30 2003-05-22 新規なエトノゲストレルエステルの使用
ES03755980T ES2305498T3 (es) 2002-05-30 2003-05-22 Uso de nuevos esteres de etonogestrel.
YU101004A RS101004A (en) 2002-05-30 2003-05-22 Use of new etonogestrel esters
DE60320786T DE60320786D1 (de) 2002-05-30 2003-05-22 Verwendung neuer etonogestrelester
US10/517,362 US20050222114A1 (en) 2002-05-30 2003-05-22 Use of new etonogestrel esters
AU2003246740A AU2003246740B2 (en) 2002-05-30 2003-05-22 Use of new etonogestrel esters
MXPA04011798A MXPA04011798A (es) 2002-05-30 2003-05-22 Uso de nuevos esteres de etonogestrel.
NZ536618A NZ536618A (en) 2002-05-30 2003-05-22 An oily pharmaceutical composition for use as contraceptive and/or HRT comprising etonogesterel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate
UA20041109285A UA80703C2 (en) 2002-05-30 2003-05-22 Pharmaceutical composition comprising etonogestrel esters and use thereof for contraception and hormone replacement therapy
KR10-2004-7019327A KR20050005507A (ko) 2002-05-30 2003-05-22 신규한 에토노게스트렐 에스테르의 용도
BR0311248-9A BR0311248A (pt) 2002-05-30 2003-05-22 Kit de contracepção e/ou de hrt, usos de um éster de etonogestrel de ação prolongada, de um éster de etonogestrel de ação prolongada em conjunto com um éster de andrógeno de ação prolongada e de um éster de etonogestrel de ação prolongada em conjunto com um estrogênio, e, métodos de contracepção e /ou de hrt e de tratamento e/ou de prevenção de um distúrbio ginecológico feminino
EP03755980A EP1513588B1 (fr) 2002-05-30 2003-05-22 Utilisation de nouveaux esters d'etonogestrel
CA002487293A CA2487293A1 (fr) 2002-05-30 2003-05-22 Utilisation de nouveaux esters d'etonogestrel
IL16512504A IL165125A0 (en) 2002-05-30 2004-11-09 Use of new etonogestrel esters
NO20044903A NO20044903L (no) 2002-05-30 2004-11-10 Anvendelse av nye etonogestrel estere
IS7537A IS7537A (is) 2002-05-30 2004-11-18 Notkun á nýjum etónógestrel esterum.
HR20041127A HRP20041127A2 (en) 2002-05-30 2004-11-25 Use of new etonogestrel esters
HK05105351A HK1072568A1 (en) 2002-05-30 2005-06-28 Use of new etonogestrel esters

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077118 2002-05-30
EP02077118.4 2002-05-30

Publications (2)

Publication Number Publication Date
WO2003101374A2 WO2003101374A2 (fr) 2003-12-11
WO2003101374A3 true WO2003101374A3 (fr) 2004-02-26

Family

ID=29595013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/050188 WO2003101374A2 (fr) 2002-05-30 2003-05-22 Utilisation de nouveaux esters d'etonogestrel

Country Status (27)

Country Link
US (1) US20050222114A1 (fr)
EP (1) EP1513588B1 (fr)
JP (1) JP2005532336A (fr)
KR (1) KR20050005507A (fr)
CN (1) CN1655848A (fr)
AR (1) AR040129A1 (fr)
AT (1) ATE394140T1 (fr)
AU (1) AU2003246740B2 (fr)
BR (1) BR0311248A (fr)
CA (1) CA2487293A1 (fr)
DE (1) DE60320786D1 (fr)
ES (1) ES2305498T3 (fr)
HK (1) HK1072568A1 (fr)
HR (1) HRP20041127A2 (fr)
IL (1) IL165125A0 (fr)
IS (1) IS7537A (fr)
MX (1) MXPA04011798A (fr)
NO (1) NO20044903L (fr)
NZ (1) NZ536618A (fr)
PE (1) PE20040042A1 (fr)
PL (1) PL373295A1 (fr)
RS (1) RS101004A (fr)
RU (1) RU2322986C2 (fr)
TW (1) TW200400041A (fr)
UA (1) UA80703C2 (fr)
WO (1) WO2003101374A2 (fr)
ZA (1) ZA200409498B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters
US20130123523A1 (en) * 2011-11-10 2013-05-16 Klaus Nickisch Methods for the preparation of etonogestrel and desogestrel
DE102012211511A1 (de) * 2012-07-03 2014-01-09 Siemens Aktiengesellschaft Bestimmung der Eignung einer Ressource
WO2019078983A1 (fr) * 2017-10-19 2019-04-25 Evestra, Inc. Contraceptifs de promédicament de progestine à action prolongée
CN111057120B (zh) * 2019-12-27 2021-04-27 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途
US20230227492A1 (en) * 2020-06-11 2023-07-20 The Usa As Represented By The Secretary, Department Of Health And Human Services Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004157A1 (fr) * 1992-08-21 1994-03-03 Schering Aktiengesellschaft Agent d'application transdermique contenant du 3-ceto-desogestrel
DE4240806A1 (de) * 1992-12-01 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
JPH07101884A (ja) * 1993-10-01 1995-04-18 Sanei Gen F F I Inc 水溶性ヘミセルロースを含有する製剤
EP0737477A1 (fr) * 1993-12-27 1996-10-16 Akzo Nobel N.V. Preparation pour absorption par voie percutanee
WO1997003709A1 (fr) * 1995-07-17 1997-02-06 Schering Aktiengesellschaft Agent pour application transdermique contenant des esters de 3-ketodesogestrel
WO1999067270A1 (fr) * 1998-06-19 1999-12-29 Akzo Nobel N.V. Esters d'acide cycloalkyl-carboxylique de 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha-methyltestosterone)
WO1999067271A1 (fr) * 1998-06-19 1999-12-29 Akzo Nobel N.V. Derive de testosterone
WO2000042942A2 (fr) * 1999-01-26 2000-07-27 Place Virgil A Systeme d'administration medicamenteuse par voie buccale destine a la contraception masculine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004157A1 (fr) * 1992-08-21 1994-03-03 Schering Aktiengesellschaft Agent d'application transdermique contenant du 3-ceto-desogestrel
DE4240806A1 (de) * 1992-12-01 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
JPH07101884A (ja) * 1993-10-01 1995-04-18 Sanei Gen F F I Inc 水溶性ヘミセルロースを含有する製剤
EP0737477A1 (fr) * 1993-12-27 1996-10-16 Akzo Nobel N.V. Preparation pour absorption par voie percutanee
WO1997003709A1 (fr) * 1995-07-17 1997-02-06 Schering Aktiengesellschaft Agent pour application transdermique contenant des esters de 3-ketodesogestrel
WO1999067270A1 (fr) * 1998-06-19 1999-12-29 Akzo Nobel N.V. Esters d'acide cycloalkyl-carboxylique de 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha-methyltestosterone)
WO1999067271A1 (fr) * 1998-06-19 1999-12-29 Akzo Nobel N.V. Derive de testosterone
WO2000042942A2 (fr) * 1999-01-26 2000-07-27 Place Virgil A Systeme d'administration medicamenteuse par voie buccale destine a la contraception masculine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199524, Derwent World Patents Index; AN 1995-182895, XP002265978 *

Also Published As

Publication number Publication date
ES2305498T3 (es) 2008-11-01
TW200400041A (en) 2004-01-01
JP2005532336A (ja) 2005-10-27
IL165125A0 (en) 2005-12-18
NO20044903L (no) 2005-02-25
CN1655848A (zh) 2005-08-17
CA2487293A1 (fr) 2003-12-11
RU2004138809A (ru) 2005-06-10
WO2003101374A2 (fr) 2003-12-11
HRP20041127A2 (en) 2005-02-28
AR040129A1 (es) 2005-03-16
ATE394140T1 (de) 2008-05-15
EP1513588A2 (fr) 2005-03-16
MXPA04011798A (es) 2005-03-31
PE20040042A1 (es) 2004-01-31
AU2003246740A1 (en) 2003-12-19
PL373295A1 (en) 2005-08-22
NZ536618A (en) 2007-06-29
KR20050005507A (ko) 2005-01-13
BR0311248A (pt) 2005-03-15
RS101004A (en) 2006-10-27
DE60320786D1 (de) 2008-06-19
HK1072568A1 (en) 2005-09-02
AU2003246740B2 (en) 2009-01-08
IS7537A (is) 2004-11-18
EP1513588B1 (fr) 2008-05-07
US20050222114A1 (en) 2005-10-06
ZA200409498B (en) 2006-05-31
RU2322986C2 (ru) 2008-04-27
UA80703C2 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
AU5373999A (en) New unsaturated oxime derivatives and the use thereof as latent acids
AU2001262830A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
HUP0400521A3 (en) Use of cci-779 as an antineoplastic agent
AU2001273296A1 (en) Concrete construction employing the use of a ductile strip
AU2001242573A1 (en) Mandibular advancer and method of installing the same
BR0311254A (pt) Composto, kit contraceptivo e/ou de hrt, uso de uma quantidade contraceptiva e/ou terapeuticamente eficaz de um composto, e, métodos de contracepção e/ou hrt, e de tratamento e/ou de prevenção de um distúrbio ginecológico feminino
AU2002353777A1 (en) Saliva-based methods for preventing and assessing the risk of diseases
AU2003222083A1 (en) Acid and ester compounds and methods of using the same
AU2002341321A1 (en) Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
WO2003101374A3 (fr) Utilisation de nouveaux esters d'etonogestrel
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU2001265907A1 (en) Phenolate-containing formulation with low freezing point
AU4384600A (en) Luminescent 4-trifluoromethyl-2-quinolones with long-wave uv-absorption and the use thereof
AU2002301109A1 (en) Method for the prediction of preeclampsia and other diseases
AU2002212281A1 (en) Anti-inflammatory active ingredients
AU2000244990A1 (en) Footwear structure and method of forming the same
HK1048120B (zh) 噻吩並吡啶衍生物及其作為抗炎劑的應用
EP1534293A4 (fr) Compositions anti-inflammatoires et procedes d'utilisation
AU2001233588A1 (en) New toralactone and its derivation and the use of decreasing blood-fat and losing weight
AU2001296850A1 (en) Split-ubiquitin based reporter systems and methods of their use
AU2001257467A1 (en) Footwear structure and method of forming the same
AU2001264334A1 (en) Anchor and nut assembly
AU6485200A (en) The method of burning metal fuel
AU2002354217A1 (en) Support for a double safety net which is used during the construction of buildings and similar

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-1010/04

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003755980

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 536618

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004/09498

Country of ref document: ZA

Ref document number: 2003246740

Country of ref document: AU

Ref document number: 200409498

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: P20041127A

Country of ref document: HR

Ref document number: 2487293

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/011798

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 20038123657

Country of ref document: CN

Ref document number: 2004508732

Country of ref document: JP

Ref document number: 1020047019327

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 373295

Country of ref document: PL

Ref document number: 1-2004-501961

Country of ref document: PH

Ref document number: 10517362

Country of ref document: US

Ref document number: 2712/CHENP/2004

Country of ref document: IN

Ref document number: 1200401273

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 04128951

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2004138809

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020047019327

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003755980

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003755980

Country of ref document: EP